
## Michelle T Long

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/541446/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
2	Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2524-2532.e2.	4.4	19
3	Alcohol Consumption and Cardiovascular Health. American Journal of Medicine, 2022, 135, 1213-1230.e3.	1.5	11
4	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics, 2022, 54, 761-771.	21.4	68
5	Low-Carbohydrate Diets, but Not Low-Fat Diets, Increase Non-alcoholic Fatty Liver Disease Risk in the Framingham Heart Study. Current Developments in Nutrition, 2022, 6, 962.	0.3	0
6	The GH/IGF-1 Axis Is Associated With Intrahepatic Lipid Content and Hepatocellular Damage in Overweight/Obesity. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3624-e3632.	3.6	19
7	AGA Clinical Practice Update: Diagnosis and Management ofÂNonalcoholic Fatty Liver Disease in Lean Individuals: ExpertÂReview. Gastroenterology, 2022, 163, 764-774.e1.	1.3	92
8	MELD–Na Is More Strongly Associated with Risk of Infection and Outcomes Than Other Characteristics of Patients with Cirrhosis. Digestive Diseases and Sciences, 2021, 66, 247-256.	2.3	4
9	Adherence to Ideal Cardiovascular Health Metrics Is Associated With Reduced Odds of Hepatic Steatosis. Hepatology Communications, 2021, 5, 74-82.	4.3	7
10	Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology, 2021, 73, 548-559.	7.3	49
11	Association Between Liver Fat and Bone Density is Confounded by General and Visceral Adiposity in a Communityâ€Based Cohort. Obesity, 2021, 29, 595-600.	3.0	4
12	Equal Opportunity: Women Representation on Editorial Boards and Authorship of Editorials in Gastroenterology and Hepatology Journals. American Journal of Gastroenterology, 2021, 116, 613-616.	0.4	15
13	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	7.3	102
14	Radiographic Hepatic Steatosis Is Not Associated With Key Clinical Outcomes Among Patients Hospitalized With COVID-19. Gastroenterology Research, 2021, 14, 179-183.	1.3	6
15	Sex Differences in the Associations of Visceral Adipose Tissue and Cardiometabolic and Cardiovascular Disease Risk: The Framingham Heart Study. Journal of the American Heart Association, 2021, 10, e019968.	3.7	33
16	Incidence of liverâ€related morbidity and mortality in a population cohort of nonâ€alcoholic fatty liver disease. Liver International, 2021, 41, 2590-2600.	3.9	10
17	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 1506-1507.	4.4	0
18	Quantification of gastric mucosal microcirculation as a surrogate marker of portal hypertension by spatially resolved subdiffuse reflectance spectroscopy in diagnosis of cirrhosis: a proof-of-concept study. Gastrointestinal Endoscopy, 2021, 94, 60-67.e1.	1.0	1

MICHELLE T LONG

#	Article	IF	CITATIONS
19	Cognitive Function, Sarcopenia, and Inflammation Are Strongly Associated with Frailty: A Framingham Cohort Study. American Journal of Medicine, 2021, 134, 1530-1538.	1.5	17
20	How to Promote Career Advancement and Gender Equity for Women in Gastroenterology: A Multifaceted Approach. Gastroenterology, 2021, 161, 792-797.	1.3	7
21	Increasing Liver Fat Is Associated With Incident Cardiovascular Risk Factors. Clinical Gastroenterology and Hepatology, 2020, 18, 1884-1886.	4.4	7
22	Alcohol Use Is Associated With Hepatic Steatosis Among Persons With Presumed Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 1831-1841.e5.	4.4	48
23	The association of nonâ€alcoholic fatty liver disease and cardiac structure and function—Framingham Heart Study. Liver International, 2020, 40, 2445-2454.	3.9	21
24	MAFLD vs NAFLD: Let the contest begin!. Liver International, 2020, 40, 2079-2081.	3.9	34
25	Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease. Metabolism: Clinical and Experimental, 2020, 111, 154259.	3.4	42
26	FIB-4 stage of liver fibrosis is associated with incident heart failure with preserved, but not reduced, ejection fraction among people with and without HIV or hepatitis C. Progress in Cardiovascular Diseases, 2020, 63, 184-191.	3.1	25
27	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 1651-1652.	4.4	1
28	Increasing liver fat is associated with progression of cardiovascular risk factors. Liver International, 2020, 40, 1339-1343.	3.9	15
29	Metabolomics Insights into Osteoporosis Through Association With Bone Mineral Density. Journal of Bone and Mineral Research, 2020, 36, 729-738.	2.8	37
30	Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. Liver International, 2019, 39, 1535-1544.	3.9	23
31	Gastrointestinal and liver diseases and atrial fibrillation: a review of the literature. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481983223.	3.2	15
32	Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1157-1164.e4.	4.4	62
33	Early predictors of outcomes of hospitalization for cirrhosis and assessment of the impact of race and ethnicity at safety-net hospitals. PLoS ONE, 2019, 14, e0211811.	2.5	17
34	Increased Diet Quality is Associated with Longâ€Term Reduction of Abdominal and Pericardial Fat. Obesity, 2019, 27, 670-677.	3.0	13
35	Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2019, 64, 2031-2038.	2.3	19
36	Nonalcoholic Fatty Liver Disease and Obesity Treatment. Current Obesity Reports, 2019, 8, 220-228.	8.4	68

3

MICHELLE T LONG

#	Article	IF	CITATIONS
37	A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease. Diabetes, 2019, 68, 1073-1083.	0.6	41
38	Parental nonâ€alcoholic fatty liver disease increases risk of nonâ€alcoholic fatty liver disease in offspring. Liver International, 2019, 39, 740-747.	3.9	26
39	The immunityâ€related GTPase M rs13361189 variant does not increase the risk for prevalent or incident steatosis; results from the Framingham Heart Study. Liver International, 2019, 39, 1022-1026.	3.9	3
40	Single Nucleotide Polymorphism Facilitated Down-Regulation of the Cohesin Stromal Antigen-1: Implications for Colorectal Cancer Racial Disparities. Neoplasia, 2018, 20, 289-294.	5.3	7
41	Improved Diet Quality Associates With Reduction in Liver Fat, Particularly in Individuals With High Genetic Risk Scores for Nonalcoholic Fatty Liver Disease. Gastroenterology, 2018, 155, 107-117.	1.3	127
42	A simple clinical model predicts incident hepatic steatosis in a communityâ€based cohort: The Framingham Heart Study. Liver International, 2018, 38, 1495-1503.	3.9	34
43	Visceral and Intrahepatic Fat Are Associated with Cardiometabolic Risk Factors Above Other Ectopic Fat Depots: The Framingham Heart Study. American Journal of Medicine, 2018, 131, 684-692.e12.	1.5	77
44	Prevalent Cardiovascular Disease Events and T1 Mapping Defined Hepatic Fibrosis. Circulation: Cardiovascular Imaging, 2018, 11, e007553.	2.6	5
45	Longitudinal Associations of Pericardial and Intrathoracic Fat With Progression of Coronary Artery Calcium (from the Framingham Heart Study). American Journal of Cardiology, 2018, 121, 162-167.	1.6	10
46	Intensive Pharmacy Care Improves Outcomes of Hepatitis C Treatment in a Vulnerable Patient Population at a Safety-Net Hospital. Digestive Diseases and Sciences, 2018, 63, 3241-3249.	2.3	7
47	Upper Body Subcutaneous Fat Is Associated with Cardiometabolic Risk Factors. American Journal of Medicine, 2017, 130, 958-966.e1.	1.5	41
48	Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study. Journal of the American Heart Association, 2017, 6, .	3.7	37
49	Residential Proximity to Major Roadways, Fine Particulate Matter, and Hepatic Steatosis. American Journal of Epidemiology, 2017, 186, 857-865.	3.4	35
50	Glutaredoxin-1 Deficiency Causes Fatty Liver and Dyslipidemia by Inhibiting Sirtuin-1. Antioxidants and Redox Signaling, 2017, 27, 313-327.	5.4	42
51	Association of Multiorgan Computed Tomographic Phenomap With Adverse Cardiovascular Health Outcomes. JAMA Cardiology, 2017, 2, 1236.	6.1	19
52	Bi-directional analysis between fatty liver and cardiovascular disease risk factors. Journal of Hepatology, 2017, 66, 390-397.	3.7	152
53	Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. JCI Insight, 2017, 2, .	5.0	62
54	Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. Journal of Clinical Investigation, 2017, 127, 4394-4402.	8.2	115

MICHELLE T LONG

2.4

2.2

68

#	Article	IF	CITATIONS
55	The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study. PLoS ONE, 2016, 11, e0157517.	2.5	25
56	Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study. Hepatology, 2016, 64, 1547-1558.	7.3	64
57	Development and Validation of the Framingham Steatosis Index to Identify Persons With Hepatic Steatosis. Clinical Gastroenterology and Hepatology, 2016, 14, 1172-1180.e2.	4.4	76
58	Metabolomic Profiling in Relation to New-Onset Atrial Fibrillation (from the Framingham Heart) Tj ETQq0 0 0 rgBT	/Overlock 1.6	10 Tf 50 62 27
59	The Framingham Heart Study — 67 years of discovery in metabolic disease. Nature Reviews Endocrinology, 2016, 12, 177-183.	9.6	48
60	Hepatic steatosis is associated with lower levels of physical activity measured via accelerometry. Obesity, 2015, 23, 1259-1266.	3.0	20
61	Unanswered Questions. JAMA - Journal of the American Medical Association, 2015, 313, 204.	7.4	1
62	Fat Quality and Incident Cardiovascular Disease, All-Cause Mortality, and Cancer Mortality. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 227-234.	3.6	73

Female authorship in major academic gastroenterology journals: a look over 20 years. Gastrointestinal Endoscopy, 2015, 81, 1440-1447.e3.

CT-Guided Core Needle Biopsy of Breast Lesions Visible Only on MRI. American Journal of Roentgenology, 2007, 189, 152-154.

Nonalcoholic Fatty Liver Disease and Vascular Function. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1284-1291.

64